Src kinase in complex with a quinazoline inhibitor
The structure was published by Hennequin, L.F., Allen, J., Breed, J., et al., Ple, P.A., Warin, N., and Costello, G., in 2006 in a paper entitled "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor." (abstract).
This crystal structure was determined using X-ray diffraction at a resolution of 2.2 Å and deposited in 2006.
The experimental data on which the structure is based was also deposited.
The PDB entry contains the structure of Proto-oncogene tyrosine-protein kinase Src. This molecule has the UniProt identifier P12931 (SRC_HUMAN). The sample contained 535 residues which is 100% of the natural sequence. Out of 535 residues 444 were observed and are deposited in the PDB.
It also contains one or more heterogenic compounds (e.g., ligands, co-factors, ions, modified amino acids, etc.); see here for a complete list.
The molecule is most likely monomeric.
The following tables show cross-reference information to other databases (to obtain a list of all PDB entries sharing the same property or classification, click on the magnifying glass icon):
This entry contains 1 unique UniProt protein: